R J Hicks

Summary

Affiliation: Peter MacCallum Cancer Centre
Country: Australia

Publications

  1. pmc Hybrid imaging is the future of molecular imaging
    Rj Hicks
    Centre for Molecular Imaging and Translational Medicine, Peter MacCallum Cancer Centre, Victoria, Australia
    Biomed Imaging Interv J 3:e49. 2007
  2. pmc White fat, factitious hyperglycemia, and the role of FDG PET to enhance understanding of adipocyte metabolism
    Michael S Hofman
    Center for Cancer Imaging, Peter MacCallum Cancer Centre, St, Andrews Place, East Melbourne, VIC 3002 Australia
    EJNMMI Res 1:2. 2011
  3. pmc Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies
    Andrew M Scott
    Centre for PET, Ludwig Institute for Cancer Research and Ludwig Oncology Unit, Austin Hospital, Studley Road, Heidelberg, Victoria, 3084, Australia
    EJNMMI Res 2:31. 2012
  4. doi request reprint Is there still a role for SPECT-CT in oncology in the PET-CT era?
    Rodney J Hicks
    University of Melbourne, Departments of Medicine and Radiology, The Peter MacCallum Cancer Centre, 7 St Andrew s Place, Melbourne, VIC 3002, Australia
    Nat Rev Clin Oncol 9:712-20. 2012
  5. pmc Should positron emission tomography/computed tomography be the first rather than the last test performed in the assessment of cancer?
    Rodney J Hicks
    The Sir Peter MacCallum Oncology Department, The University of Melbourne, Victoria, Australia
    Cancer Imaging 12:315-23. 2012
  6. pmc 'MRI-negative PET-positive' temporal lobe epilepsy (TLE) and mesial TLE differ with quantitative MRI and PET: a case control study
    Ross P Carne
    Victorian Epilepsy Centre, St Vincent s Hospital, Melbourne, Australia
    BMC Neurol 7:16. 2007
  7. doi request reprint Role of 18F-FDG PET in assessment of response in non-small cell lung cancer
    Rodney J Hicks
    Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    J Nucl Med 50:31S-42S. 2009
  8. ncbi request reprint Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent
    Rodney J Hicks
    Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Locked Bag No 1, A Beckett St, Melbourne 8006, Australia
    Eur J Nucl Med Mol Imaging 32:1384-91. 2005
  9. pmc The role of PET in monitoring therapy
    Rodney J Hicks
    The Centre for Molecular Imaging, The Peter MacCallum Cancer Centre, Melbourne, Australia
    Cancer Imaging 5:51-7. 2005
  10. pmc Functional imaging techniques for evaluation of sarcomas
    Rodney J Hicks
    The Centre for Molecular Imaging, The Peter MacCallum Cancer Centre, Melbourne, Australia
    Cancer Imaging 5:58-65. 2005

Detail Information

Publications121 found, 100 shown here

  1. pmc Hybrid imaging is the future of molecular imaging
    Rj Hicks
    Centre for Molecular Imaging and Translational Medicine, Peter MacCallum Cancer Centre, Victoria, Australia
    Biomed Imaging Interv J 3:e49. 2007
    ..A new era of cancer imaging, when hybrid imaging will be the primary diagnostic tool, is approaching...
  2. pmc White fat, factitious hyperglycemia, and the role of FDG PET to enhance understanding of adipocyte metabolism
    Michael S Hofman
    Center for Cancer Imaging, Peter MacCallum Cancer Centre, St, Andrews Place, East Melbourne, VIC 3002 Australia
    EJNMMI Res 1:2. 2011
    ..We discuss the potential biological basis of this finding and provide recommendations on the avoidance of this complication...
  3. pmc Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies
    Andrew M Scott
    Centre for PET, Ludwig Institute for Cancer Research and Ludwig Oncology Unit, Austin Hospital, Studley Road, Heidelberg, Victoria, 3084, Australia
    EJNMMI Res 2:31. 2012
    ..abstract:..
  4. doi request reprint Is there still a role for SPECT-CT in oncology in the PET-CT era?
    Rodney J Hicks
    University of Melbourne, Departments of Medicine and Radiology, The Peter MacCallum Cancer Centre, 7 St Andrew s Place, Melbourne, VIC 3002, Australia
    Nat Rev Clin Oncol 9:712-20. 2012
    ..The efficiency and cost savings associated with improved diagnosis and clinical decision-making provided by PET-CT make a cogent argument for it becoming the dominant molecular technique in oncology...
  5. pmc Should positron emission tomography/computed tomography be the first rather than the last test performed in the assessment of cancer?
    Rodney J Hicks
    The Sir Peter MacCallum Oncology Department, The University of Melbourne, Victoria, Australia
    Cancer Imaging 12:315-23. 2012
    ..A randomized trial design is described that could be used to test this hypothesis...
  6. pmc 'MRI-negative PET-positive' temporal lobe epilepsy (TLE) and mesial TLE differ with quantitative MRI and PET: a case control study
    Ross P Carne
    Victorian Epilepsy Centre, St Vincent s Hospital, Melbourne, Australia
    BMC Neurol 7:16. 2007
    ..We aimed to compare TLE with hippocampal sclerosis (HS+ve) and non lesional TLE without HS (HS-ve) on MRI, with respect to quantitative FDG-PET and MRI measures...
  7. doi request reprint Role of 18F-FDG PET in assessment of response in non-small cell lung cancer
    Rodney J Hicks
    Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    J Nucl Med 50:31S-42S. 2009
    ..In this review, theoretic considerations and current evidence supporting the role of (18)F-FDG PET are discussed...
  8. ncbi request reprint Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent
    Rodney J Hicks
    Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Locked Bag No 1, A Beckett St, Melbourne 8006, Australia
    Eur J Nucl Med Mol Imaging 32:1384-91. 2005
    ..The purpose of the study was to evaluate [(18)F]fluoromisonidazole (FMISO) PET in advanced head and neck cancer during hypoxia-targeting therapy...
  9. pmc The role of PET in monitoring therapy
    Rodney J Hicks
    The Centre for Molecular Imaging, The Peter MacCallum Cancer Centre, Melbourne, Australia
    Cancer Imaging 5:51-7. 2005
    ..In this review, the potential benefits and limitations of FDG PET are discussed along with suggestions regarding the most practical methodologies for response evaluation using this modality...
  10. pmc Functional imaging techniques for evaluation of sarcomas
    Rodney J Hicks
    The Centre for Molecular Imaging, The Peter MacCallum Cancer Centre, Melbourne, Australia
    Cancer Imaging 5:58-65. 2005
    ..This review aims to address the range of nuclear medicine techniques available for evaluation of bone and soft tissue sarcomas. A subsequent review discusses the clinical application of these techniques with a particular focus on PET...
  11. pmc Clinical applications of molecular imaging in sarcoma evaluation
    Rodney J Hicks
    Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia
    Cancer Imaging 5:66-72. 2005
    ..These include biopsy guidance, whole body staging, therapeutic response assessment and evaluation of residual mass lesions after treatment...
  12. ncbi request reprint Initial staging of lymphoma with positron emission tomography and computed tomography
    Rodney J Hicks
    Centre for Molecular Imaging, Peter MacCallum Cancer Centre, 12 Cathedral Place, East Melbourne, Victoria 3002, Australia
    Semin Nucl Med 35:165-75. 2005
    ..In our institution, FDG PET/CT has become the preferred initial staging tool for patients with lymphoma...
  13. doi request reprint PET/MRI: a different spin from under the rim
    Rodney J Hicks
    Centre for Molecular Imaging, The Peter MacCallum Cancer Centre, 12 St Andrew s Place, East Melbourne, Vic, 3002, Australia
    Eur J Nucl Med Mol Imaging 36:S10-4. 2009
    ....
  14. pmc PET/CT: will it change the way that we use CT in cancer imaging?
    Rodney J Hicks
    Centre for Molecular Imaging, The Peter MacCallum Cancer Centre, Melbourne, Australia
    Cancer Imaging 6:S52-62. 2006
    ..Primary staging of oesophageal cancer and restaging of colorectal cancer are illustrative examples of a new paradigm for cancer imaging...
  15. ncbi request reprint The SUV and FLT PET: a tasty alphabet soup or a dog's breakfast?
    Rodney J Hicks
    Centre for Molecular Imaging, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia
    Leuk Lymphoma 48:649-52. 2007
  16. ncbi request reprint Ga-67 SPECT: ave atque vale! Or have we bid a premature farewell to a trusted friend?
    Rodney J Hicks
    The Peter MacCallum Cancer Centre, and the University of Melbourne, Australia
    Leuk Lymphoma 47:2440-2. 2006
  17. ncbi request reprint The evolving role of fluorodeoxyglucose positron emission tomography (FDG PET) in lymphoma: how do we reconcile conflicting results in the era of evidence-based medicine?
    Rodney J Hicks
    Peter MacCallum Cancer Centre, Melbourne, Vic, 3002, Australia
    Leuk Lymphoma 47:2008-10. 2006
  18. pmc Beyond FDG: novel PET tracers for cancer imaging
    Rodney J Hicks
    Centre for Molecular Imaging, The Peter MacCallum Cancer Centre, Melbourne, Australia
    Cancer Imaging 4:22-4. 2004
    ..Due to the general availability and favourable physical properties of fluorine-18, much effort has been directed to fluorinated compounds. The most promising of these are discussed...
  19. pmc PET tracer development--a tale of mice and men
    Rodney J Hicks
    Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia
    Cancer Imaging 6:S102-6. 2006
    ..Nevertheless, application of a systematic approach to tracer development is likely to speed transition of new tracers from animals into man...
  20. ncbi request reprint Imaging in the diagnosis and treatment of non-small cell lung cancer
    Rodney J Hicks
    Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Respirology 12:165-72. 2007
    ....
  21. doi request reprint Time and again, children resemble their parents
    Rodney J Hicks
    Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Victoria, Australia
    J Nucl Med 49:1577-8. 2008
  22. pmc Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy
    R J Hicks
    Departments of Medicine and Radiology, University of Melbourne, Centre for Cancer Imaging, Molecular Imaging and Targeted Therapeutics Laboratory, The Peter MacCallum Cancer Centre, East Melbourne, Australia
    Cancer Imaging 10:S83-91. 2010
    ..In the future, paradigms guided by clinical and biopsy features should allow personalized imaging paradigms aligned to therapeutic options...
  23. ncbi request reprint High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy
    M P MacManus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 50:287-93. 2001
    ..We tested the hypothesis that positron emission tomography (PET) using 18-F fluorodeoxyglucose (FDG) would detect more unsuspected metastases in apparent Stage III disease than in Stages I-II...
  24. ncbi request reprint (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer
    R J Hicks
    Department of Diagnostic Imaging, Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
    J Nucl Med 42:1596-604. 2001
    ..Further, the additional information provided by PET significantly and appropriately changed management in the majority of patients...
  25. ncbi request reprint The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification
    R J Hicks
    Department of Diagnostic Imaging, Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
    J Nucl Med 42:1605-13. 2001
    ..CONCLUSION: PET better assesses the status of disease and stratifies prognosis than does conventional staging, affects patient management, and should be incorporated into paradigms for suspected recurrence of NSCLC...
  26. ncbi request reprint F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment
    M P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, A Beckett Street, Melbourne, Victoria 3000, Australia
    Cancer 92:886-95. 2001
    ..The authors investigated FDG-PET staging in radical RT candidates with unresectable NSCLC...
  27. ncbi request reprint Imaging with F-18 FDG PET is superior to Tl-201 SPECT in the staging of non-small cell lung cancer for radical radiation therapy
    M P MacManus
    Division of Radiation Oncology and Department of Diagnostic Imaging, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Australas Radiol 45:483-90. 2001
    ....
  28. ncbi request reprint Positron emission tomography in pulmonary masses where tissue diagnosis is unhelpful or not possible
    A G Pitman
    Department of Diagnostic Imaging, Peter MacCallum Cancer Institute, East Melbourne, Vic
    Med J Aust 175:303-7. 2001
    ..To document the usefulness of positron emission tomography (PET) in diagnosing lung masses where tissue diagnosis is not possible or is unhelpful...
  29. ncbi request reprint "Magnetic resonance imaging negative positron emission tomography positive" temporal lobe epilepsy: FDG-PET pattern differs from mesial temporal lobe epilepsy
    R P Carne
    Victorian Epilepsy Centre, St Vincent s Hospital, Melbourne, Victoria, Australia
    Mol Imaging Biol 9:32-42. 2007
    ....
  30. pmc FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy
    F L Day
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett Street, Melbourne, 8006, Victoria, Australia
    Br J Cancer 105:498-504. 2011
    ..The aim was to investigate the correlation between (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) metabolic response to chemoradiotherapy and clinical outcomes in squamous cell carcinoma (SCC) of the anus...
  31. pmc Overview of early response assessment in lymphoma with FDG-PET
    Michael P MacManus
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, VIC 3002, Australia
    Cancer Imaging 7:10-8. 2007
    ....
  32. doi request reprint The impact of 18-fluorodeoxyglucose positron emission tomography-computed tomography on the staging and management of primary rectal cancer
    K Davey
    Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Dis Colon Rectum 51:997-1003. 2008
    ..18-Fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) has a role in recurrent colorectal cancer. This study was designed to assess the impact of PET-CT on management of primary rectal cancer...
  33. doi request reprint Metabolic response of rectal cancer assessed by 18-FDG PET following chemoradiotherapy is prognostic for patient outcome
    J M C Yeung
    Department of Surgical Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, Victoria, Australia
    Dis Colon Rectum 54:518-25. 2011
    ..Sequential 18-FDG PET may be an early surrogate for pathological response to chemoradiotherapy...
  34. ncbi request reprint Relation between FIGO stage, primary tumor volume, and presence of lymph node metastases in cervical cancer patients referred for radiotherapy
    K Narayan
    Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Int J Gynecol Cancer 13:657-63. 2003
    ..This may provide clinically important prognostic information not available from current FIGO staging...
  35. ncbi request reprint A comparison of MRI and PET scanning in surgically staged loco-regionally advanced cervical cancer: potential impact on treatment
    K Narayan
    Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia, Monash Medical Center, Melbourne, Victoria, Australia
    Int J Gynecol Cancer 11:263-71. 2001
    ..MRI has insufficient accuracy for nodal staging to impact management...
  36. ncbi request reprint Positron emission tomography (PET): experience with a large-field-of-view three-dimensional PET scanner
    R J Hicks
    Peter MacCallum Cancer Institute, Melbourne, Vic
    Med J Aust 171:529-32. 1999
    ..Optimised for clinical service, PET offers lower scanning costs and therefore improved cost-effectiveness...
  37. ncbi request reprint Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer
    Sandro V Porceddu
    Division of Radiation Oncology, St Andrews Place, East Melbourne, Australia
    Head Neck 27:175-81. 2005
    ....
  38. ncbi request reprint Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck
    Robert E Ware
    The Department of Diagnostic Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Head Neck 26:1008-17. 2004
    ..The usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) to supplement conventional evaluation with clinical and standard radiologic examination (CE) in such patients was assessed...
  39. ncbi request reprint Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab
    M J Bishton
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Ann Oncol 19:1629-33. 2008
    ..We examined the effects of a second (131)I-rituximab in patients with indolent lymphoma following relapse...
  40. ncbi request reprint Comparison of CT and positron emission tomography/CT coregistered images in planning radical radiotherapy in patients with non-small-cell lung cancer
    M MacManus
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Australas Radiol 51:386-93. 2007
    ..Use of coregistered PET/CT images significantly altered treatment plans in a majority of cases. This method could be used in routine practice at centres without access to a combined PET/CT scanner ...
  41. doi request reprint Radiation changes do not interfere with postchemoradiation restaging of patients with rectal cancer by FDG PET/CT before curative surgical therapy
    Victor Kalff
    Centre for Molecular Imaging, The Peter MacCallum Cancer Centre, Melbourne Australia
    Int J Radiat Oncol Biol Phys 74:60-6. 2009
    ..The positive predictive value (PPV) and specificity of post-CRT PET, read clinically, was determined in 63 consecutive rectal cancer patients who had undergone preoperative CRT...
  42. ncbi request reprint PET scanning in lung cancer: current status and future directions
    Michael P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, St Andrew s Place, East Melbourne, Vic, Australia
    Semin Surg Oncol 21:149-55. 2003
    ..PET has rapidly become an indispensable part of the evaluation of patients with potentially curable lung cancer; however, more work is required to define its role...
  43. doi request reprint Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study
    Andrew M Scott
    Centre for PET, Austin Hospital, Studley Rd, Heidelberg, Melbourne, Victoria 3084, Australia
    Eur J Nucl Med Mol Imaging 36:347-53. 2009
    ..Positron emission tomography (PET) was evaluated in low-grade non-Hodgkin lymphoma (NHL) to determine its impact on staging and management and to compare PET and gallium scans...
  44. ncbi request reprint Impact of 18F-fluorodeoxyglucose positron emission tomography in the staging and treatment response assessment of extra-pulmonary small-cell cancer
    D L Gregory
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    J Med Imaging Radiat Oncol 54:100-7. 2010
    ..PET has incremental value compared to conventional imaging for staging EPSCC, and may also be useful for restaging after therapy. PET influenced patient management in 19% of 43 imaging episodes...
  45. ncbi request reprint Patterns of failure and prognostic factor analyses in locally advanced cervical cancer patients staged by positron emission tomography and treated with curative intent
    Kailash Narayan
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Int J Gynecol Cancer 19:912-8. 2009
    ....
  46. ncbi request reprint Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma
    Caroline A Connell
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Australia
    Head Neck 29:986-95. 2007
    ..The aim of this study was to determine prospectively the incremental value of positron emission tomography/computed tomography (PET/CT) over conventional assessment (clinical examination and CT/MRI imaging)...
  47. ncbi request reprint Impact of PET on radiation therapy planning in lung cancer
    Michael P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, VIC 3002, Australia
    Radiol Clin North Am 45:627-38, v. 2007
    ..PET will allow for more accurately targeted dose escalation studies in the future and could potentially lead to better long-term survival...
  48. ncbi request reprint Role of FDG-PET/CT in staging and follow-up of head and neck squamous cell carcinoma
    D Mak
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia
    Q J Nucl Med Mol Imaging 55:487-99. 2011
    ....
  49. doi request reprint The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable
    T W Barber
    Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria 3002, Australia
    Eur J Surg Oncol 38:64-71. 2012
    ....
  50. doi request reprint Evaluation of pulmonary nodules and lung cancer with one-inch crystal gamma coincidence positron emission tomography/CT versus dedicated positron emission tomography/CT
    K Moodie
    The Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    J Med Imaging Radiat Oncol 53:32-9. 2009
    ....
  51. pmc Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial
    S Loi
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, University of Melbourne, A Beckett Street, Melbourne, Victoria 8006, Australia
    Br J Cancer 92:655-61. 2005
    ..For future trials, oxaliplatin 85 mg m(-2) and 5-FU 200 mg m(-2) day(-1) continuous infusion 96 h week(-1) is the recommended dose when combined with 50.4 Gy of pelvic radiotherapy...
  52. doi request reprint Endoscopic ultrasound-guided fine-needle aspiration when combined with positron emission tomography improves specificity and overall diagnostic accuracy in unexplained mediastinal lymphadenopathy and staging of non-small-cell lung cancer
    A V Kalade
    Department of Gastroenterology, St Vincent s Hospital, Melbourne, Victoria, Australia
    Intern Med J 38:837-44. 2008
    ....
  53. ncbi request reprint FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer
    Cuong P Duong
    Division of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Eur J Nucl Med Mol Imaging 33:770-8. 2006
    ..The purpose of this study was to evaluate the impact of FDG-PET following chemoradiotherapy (CRT) on treatment planning and survival in patients with oesophageal cancer (OC)...
  54. ncbi request reprint Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure
    Michael P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, VIC 3002, Australia
    Lung Cancer 49:95-108. 2005
    ..PET-response, survival and patterns of failure data are presented with long-term follow-up...
  55. ncbi request reprint Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma
    Andrew Wirth
    Division of Radiation Oncology, Peter McCallum Cancer Institute, East Melbourne, Victoria, Australia
    Am J Med 112:262-8. 2002
    ..To compare fluorine-18 fluorodeoxyglucose positron emission tomography (PET) and gallium scanning with each other and with conventional staging, for patients with Hodgkin's disease or non-Hodgkin's lymphoma...
  56. ncbi request reprint Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation
    Rodney J Hicks
    Centre for Molecular Imaging, The Peter MacCallum Cancer Centre, Melbourne, Australia
    Int J Radiat Oncol Biol Phys 60:412-8. 2004
    ..The prognostic significance of these changes was also studied...
  57. ncbi request reprint Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience
    Robert Blum
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, East Melbourne, Vic, Australia
    Am J Clin Oncol 27:164-71. 2004
    ..PET-CR conferred longer median time to progression (13.7 months) than no CR (9.7 months). FDG-PET for SCLC was often discordant with conventional assessment and frequently influenced management...
  58. ncbi request reprint Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure
    Ashley P Ng
    Haematology Service, PeterMacCallum Cancer Centre, Melbourne, Australia
    Leuk Lymphoma 48:596-600. 2007
    ..Low-grade FDG-avidity on interim restaging at sites of bone involvement by DLBCL at diagnosis, appears to be less predictive of disease progression than residual nodal or extra-nodal soft tissue abnormality by PET...
  59. ncbi request reprint Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery
    Victor Kalff
    Center for Molecular Imaging, The Peter MacCallum Cancer Center, Melbourne, Victoria, Australia
    J Nucl Med 47:14-22. 2006
    ..We evaluated the prognostic information obtained from the degree of change in tumor (18)F-FDG PET uptake induced by chemoradiation before radical curative surgery in patients with T3/T4 rectal cancer...
  60. ncbi request reprint In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma
    D Ritchie
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag, 1 A Beckett St, 8006 East Melbourne, Australia
    Cancer Immunol Immunother 56:155-63. 2007
    ..Incorporation of tracking studies in early cycles of cellular immunotherapy may allow selection of patients who demonstrate successful targeting of the immunotherapy for ongoing treatment...
  61. ncbi request reprint Positron emission tomography of stage IV mucosa-associated lymphoid tissue lymphoma confined to the four major salivary glands
    M P Mac Manus
    Departments of Radiation Oncology, Pater MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Australas Radiol 51:68-70. 2007
    ..After 30 Gy of external beam radiotherapy to the parotid and submandibular glands, the patient entered a complete remission and remains free from progression more than 4 years later...
  62. doi request reprint Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer
    J M Beauregard
    Centre for Molecular Imaging, Department of Cancer Imaging, University of Melbourne, Melbourne, Australia
    J Med Imaging Radiat Oncol 54:325-32. 2010
    ..We report a prospective pilot study of PET/CT comparing both tracers for staging and restaging of patients with prostate cancer...
  63. ncbi request reprint The utility of a 3-dimensional, large-field-of-view, sodium iodide crystal--based PET scanner in the presurgical evaluation of partial epilepsy
    R J Hicks
    Australian Center for Clinical Neuropharmacology, St. Vincent's Hospital, Fitzroy, Victoria, Australia
    J Nucl Med 42:1158-65. 2001
    ..The PET images provided prognostically significant localization information incremental to that provided by volumetric MRI and ictal EEG, particularly if 1 of these studies was nonlocalizing...
  64. ncbi request reprint Performance of sodium iodide based (18)F-fluorodeoxyglucose positron emission tomography in the characterization of indeterminate pulmonary nodules or masses
    A G Pitman
    Department of Diagnostic Imaging, Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne, Victoria 3002, Australia
    Br J Radiol 75:114-21. 2002
    ..Performance of sodium iodide PET is comparable with reported results for PET scanners using other detector materials...
  65. ncbi request reprint A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma
    L Mileshkin
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Eur J Haematol 72:32-7. 2004
    ..The extent of disease in patients with multiple myeloma or related conditions may be difficult to assess. In previous small studies, both FDG-PET (PET) and Tc-99m sestamibi scans (MIBI) have identified sites of occult disease in myeloma...
  66. ncbi request reprint Primary skeletal muscle marginal zone lymphoma with persistent tissue tropism and PET-avidity
    S I Gill
    Department of Haematology, St Vincent s Hospital, Melbourne, Victoria, Australia
    Leuk Lymphoma 47:117-20. 2006
    ..In this case, 18F-fluoro-deoxy-glucose positron emission tomography scanning was the most useful surveillance modality...
  67. doi request reprint The cost-effective use of 18F-FDG PET in the presurgical evaluation of medically refractory focal epilepsy
    Terence J O'Brien
    Department of Medicine, Surgery, and Neurology, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia
    J Nucl Med 49:931-7. 2008
    ..This study applied decision tree analysis to evaluate the sensitivity, specificity, and cost-effectiveness of clinical algorithms that incorporate 18F-FDG PET...
  68. ncbi request reprint Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033
    Donna S Dorow
    Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Eur J Nucl Med Mol Imaging 33:441-52. 2006
    ..This study was designed as "proof of concept" for a drug development model utilising multi-tracer serial small animal PET imaging to characterise tumour responses to molecularly targeted therapy...
  69. ncbi request reprint Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer
    Cuong P Duong
    Division of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Eur J Nucl Med Mol Imaging 33:759-69. 2006
    ..To evaluate the clinical impact of FDG-PET in staging oesophageal cancer and whether this information improves prognostic stratification...
  70. ncbi request reprint Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging
    Benjamin Solomon
    Research Division, Peter MacCallum Cancer Institute, Melbourne, Australia
    Mol Cancer Ther 4:1417-22. 2005
    ..A strong correlation was observed between pimonidazole binding and FAZA uptake. Together, these findings show that gefitinib reduces intratumoral hypoxia...
  71. ncbi request reprint The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study
    Victor Kalff
    Department of Diagnostic Imaging, Peter MacCallum Cancer Institute, 12 Cathedral Place, East Melbourne, Victoria 3002, Australia
    J Nucl Med 43:492-9. 2002
    ..This prospective study aimed to confirm, in a clinical setting, the benefits suggested by earlier retrospective studies of (18)F-FDG PET scanning for the evaluation of patients with suspected recurrence of colorectal cancer...
  72. ncbi request reprint Discordant response to chemotherapy detected by PET scanning: unveiling of a second primary cancer
    Robert Blum
    Division of Oncology at Peter MacCallum Cancer Institute, Melbourne, Australia
    Am J Clin Oncol 25:368-70. 2002
    ..A mixed response requires further investigation, particularly in the case of persisting solitary abnormalities in the neck...
  73. ncbi request reprint Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET
    Victor Kalff
    The Department of Diagnostic Imaging, The Peter MacCallum Cancer Institute, 12 Cathedral Place, East Melbourne, Victoria, 3002 Australia
    Eur J Nucl Med Mol Imaging 29:506-15. 2002
    ....
  74. ncbi request reprint Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center
    Michael P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 52:351-61. 2002
    ..We hypothesized that early cancer death rates would be lower in patients receiving RRT after PET staging compared with conventionally staged patients...
  75. ncbi request reprint Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy
    Florent Cachin
    Centre for Molecular Imaging, The Peter MacCallum Cancer Centre, 12 Cathedral Place, East Melbourne, VIC 3002, Australia
    J Clin Oncol 24:3026-31. 2006
    ....
  76. ncbi request reprint Intraperitoneal distribution imaging in ovarian cancer patients
    S J Dawson
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Intern Med J 41:167-71. 2011
    ..Optimal delivery of intraperitoneal (i.p.) chemotherapy is dependent on adequate drug distribution. An accurate understanding of the limitations of i.p. distribution is critical if we are to improve cytotoxic delivery through this route...
  77. ncbi request reprint 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy
    L Johns Putra
    Department of Surgery, University of Melbourne, Melbourne, Australia
    Urology 64:1202-7. 2004
    ..To evaluate the role of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) in the assessment of germ cell tumors after chemotherapy...
  78. ncbi request reprint Pattern of uptake and excretion of (18)F-FDG in the lactating breast
    R J Hicks
    Peter MacCallum Cancer Institute Center for PET, East Melbourne, Vic, Australia
    J Nucl Med 42:1238-42. 2001
    ..There is, however, little secretion of activity into breast milk. Accordingly, a higher radiation dose is received by the infant from close contact with the breast than from ingestion of radioactive milk...
  79. ncbi request reprint Diffuse large B-cell non-Hodgkin's lymphoma presenting as Sister Joseph's nodule
    C Tam
    Department of Haematology, Peter MacCallum Cancer Institute, St Andrew s Place, East Melbourne, VIC 3002, Australia
    Leuk Lymphoma 43:2055-7. 2002
    ..The patient's unusual histology and pattern of disease involvement are also discussed...
  80. ncbi request reprint Management of paediatric thyroid carcinoma: recent experience with recombinant human thyroid stimulating hormone in preparation for radioiodine therapy
    W F E Lau
    Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Intern Med J 36:564-70. 2006
    ..The aim of the study was to report recent experience in the management of differentiated thyroid carcinoma in children, especially in the use of radioiodine after recombinant human thyroid stimulating hormone (rhTSH) stimulation...
  81. ncbi request reprint Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma
    Robert H Blum
    Division of Hematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia
    Clin Lymphoma 4:43-9. 2003
    ..This high accuracy of FDG-PET in assessing discordant lesions suggests a greater diagnostic utility compared with CT...
  82. ncbi request reprint 18F-FDG PET in candidates for radiation therapy: is it important and how do we validate its impact?
    Rodney J Hicks
    Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    J Nucl Med 44:30-2. 2003
  83. ncbi request reprint Clinical experience with the first combined positron emission tomography/computed tomography scanner in Australia
    W F Eddie Lau
    Department of Radiology, Peter MacCallum Cancer Centre, Melbourne, Vic
    Med J Aust 182:172-6. 2005
    ..We believe PET/CT will underpin more effective and efficient imaging paradigms for many common tumours, and lead to a decrease in imaging costs...
  84. doi request reprint Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer
    Sarah Everitt
    Radiation Therapy Services, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 75:1098-104. 2009
    ..To establish whether (18)F-3'-deoxy-3'-fluoro-L-thymidine ((18)F-FLT) can monitor changes in cellular proliferation of non-small-cell lung cancer (NSCLC) during radical chemo-radiotherapy (chemo-RT)...
  85. ncbi request reprint Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer
    Michael P Mac Manus
    Department of Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
    J Clin Oncol 21:1285-92. 2003
    ..PET is known to provide a more accurate estimate of true extent of disease than CT when used to stage non-small-cell lung cancer (NSCLC)...
  86. doi request reprint High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience
    Grace Kong
    Center for Molecular Imaging, Peter MacCallum Cancer Center, East Melbourne, Victoria 3002, Australia
    Cancer Biother Radiopharm 24:527-33. 2009
    ..Combining HA-Oc with radiosensitizing 5-fluorouracil (5FU) chemotherapy could enhance efficacy. Our other aim was to assess whether concomitant 5FU would contribute to significant additional toxicity...
  87. doi request reprint Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour
    Eddie W F Lau
    Centre for Molecular Imaging, Peter MacCallum Cancer Centre, 12 Cathedral Place, East Melbourne, Victoria 3002, Australia
    J Clin Neurosci 17:43-9. 2010
    ..FDG sensitivity was 27%, specificity 90%, accuracy 52%, PPV 80% and NPV 45%. FET PET is more accurate than FDG PET for detecting malignant brain lesions, especially low-grade gliomas...
  88. doi request reprint High-contrast PET of melanoma using (18)F-MEL050, a selective probe for melanin with predominantly renal clearance
    Delphine Denoyer
    Centre for Molecular Imaging and Translational Research Laboratory, Peter MacCallum Cancer Centre, Victoria, Australia
    J Nucl Med 51:441-7. 2010
    ..The aim of this study was to evaluate the novel probe (18)F-6-fluoro-N-[2-(diethylamino)ethyl] pyridine-3-carboxamide ((18)F-MEL050) for the imaging of primary and metastatic melanoma...
  89. doi request reprint High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer
    Sarah Everitt
    Department of Radiation Oncology, Radiation Therapy Services, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Cancer 116:5030-7. 2010
    ....
  90. doi request reprint Imaging, radiation oncology and randomised trials: time for a change?
    Gillian M Duchesne
    Division of Radiation Oncology Centre for Molecular Imaging, University of Melbourne, Melbourne, Victoria, Australia
    J Med Imaging Radiat Oncol 55:97-100. 2011
    ....
  91. ncbi request reprint The role of PET-CT in the management of patients with advanced cancer of the head and neck
    June Corry
    Division of Radiation Oncology, Peter MacCallum Cancer Centre, Locked Bag No 1, A Beckett Street, Melbourne 8006, Australia
    Curr Oncol Rep 10:149-55. 2008
    ..We also demonstrate why PET-CT should be an integral part of modern management of head and neck cancer...
  92. ncbi request reprint The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor
    Gerald B Fogarty
    Division of Radiation Oncology, Peter MacCallum Cancer Institute, Locked Bag 1, A Beckett St, Victoria 8006, Australia
    Head Neck 25:138-45. 2003
    ..To assess the role of PET in this scenario in our institution, an audit was performed...
  93. doi request reprint PET for sarcomas other than gastrointestinal stromal tumors
    Guy C Toner
    Peter MacCallum Cancer Institute, Medical Oncology, St Andrews Place, East Melbourne, Australia 3002
    Oncologist 13:22-6. 2008
    ..PET imaging offers invaluable information to help maximize the clinical benefit of patients with sarcoma. This article reviews the use of PET in sarcoma management and its potential applications in the near future...
  94. ncbi request reprint A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer
    Trevor Leong
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, and Department of Medicine, University of Melbourne, Vic, Australia
    Radiother Oncol 78:254-61. 2006
    ....
  95. ncbi request reprint The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas
    Kenneth K Khamly
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Expert Rev Mol Diagn 8:105-19. 2008
    ..This article will discuss the above issues, using the setting of sarcomas as an example...
  96. doi request reprint Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma
    Andrew Wirth
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 71:213-9. 2008
    ..We evaluated the impact of fluorodeoxyglucose (FDG) PET on staging, treatment, and outcome for patients with ESFL on conventional staging...
  97. ncbi request reprint Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncolog
    Danny Rischin
    Division of Haematology and Medical Oncology, Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia
    J Clin Oncol 24:2098-104. 2006
    ....
  98. pmc Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy
    C Y Cheah
    Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia
    Br J Cancer 109:312-7. 2013
    ..The usefulness of positron emission tomography with computed tomography (PET-CT) in the surveillance of patients with diffuse large B-cell lymphoma (DLBCL) in complete metabolic remission after primary therapy is not well studied...
  99. ncbi request reprint In vivo tracking for cell therapies
    M Thompson
    Department of Diagnostic Imaging, Peter MacCallum Cancer Centre, 1 A Beckett Street, East Melbourne, Australia 8006
    Q J Nucl Med Mol Imaging 49:339-48. 2005
    ..Incorporating tracking studies into clinical trials of cell-based therapy at the earliest stage can provide proof of mechanism of the therapy and permit evaluation of the many contributory variables, even on a patient-by-patient basis...
  100. doi request reprint Imaging in follicular NHL
    M S Hofman
    Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia
    Best Pract Res Clin Haematol 24:165-77. 2011
    ..Molecular imaging is likely to play an increasing role in selection of patients for specific treatments and in prognostic stratification...